Skip to main content


Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer

Fig. 2

Pharmacological inhibition of PDK1 reduces PDAC cells proliferation in monolayer culture. Non-malignant epithelial pancreatic cells (hTERT-HPNE, HPDE) as well as PDAC cells (AsPC-1, HPAF-II) were treated with increasing concentrations of the PDK1 inhibitors GSK2334470 (a), MP7 (b) and 2-O-Bn-InsP5 (c) for 72 h, and cell viability was assessed. Data are expressed as percentage of control cells treated with vehicle alone (DMSO) and are means ± SEM of n ≥ 3 independent experiments performed in duplicate. For each cell line, one-way ANOVA with Dunnett’s multiple comparisons test was used for statistical analysis between each treatment and its corresponding DMSO-treated control. Analysis was performed with GraphPad Prism version 6.0. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page